Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus LIBERVANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus LIBERVANT.
DORAL vs LIBERVANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
15-30 mg orally at bedtime, maximum 60 mg/day.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Benzodiazepine
Benzodiazepine